文献速递心律失常

房颤与癌症共存:荷兰全国性研究中的时间趋势及与死亡率的关联

Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study.
PubMed 文献 · Eur Heart J · 2024-01-01

房颤患者中癌症患病率为12.6%(对照5.6%),癌症患者中房颤患病率为7.5%(对照4.3%);房颤后诊断癌症(aHR 7.77,95%CI 7.45-8.11)和癌症后诊断房颤(aHR 2.55,95%CI 2.47-2.63)均与全因死亡率相关。

要点

  • 房颤患者中癌症患病率12.6%,1年癌症风险2.5%(aHR 1.52)。
  • 癌症患者中房颤患病率7.5%,1年房颤风险2.8%(aHR 2.78)。
  • 房颤与癌症双向关联,且共存与全因死亡率增加相关。

核心结论

  • 房颤与癌症存在双向关联且共存趋势增加,但房颤风险因癌症类型而异。
  • 房颤与癌症共存与生存率负相关。

研究设计与样本

  • 采用时间依赖Cox回归估计癌症/房颤诊断与全因死亡率的关联。

主要发现

  • 房颤队列中癌症患病率为12.6%(从11.9%升至13.2%),对照为5.6%;1年癌症风险为2.5%(逐年稳定),对照为1.8%(aHR 1.52,95%CI 1.46-1.58),各癌症类型相似。
  • 癌症队列中房颤患病率为7.5%(从6.9%升至8.2%),对照为4.3%;1年房颤风险为2.8%(逐年稳定),对照为1.2%(aHR 2.78,95%CI 2.69-2.87),但食管癌、肺癌、胃癌、骨髓瘤和淋巴瘤的房颤风险高于其他癌症类型。
  • 房颤后诊断癌症(aHR 7.77,95%CI 7.45-8.11)和癌症后诊断房颤(aHR 2.55,95%CI 2.47-2.63)均与全因死亡率相关,关联强度因癌症类型而异。

临床怎么用

  • 对房颤患者应关注癌症筛查,尤其注意1年癌症风险高于对照。
  • 对癌症患者应监测房颤发生,食管癌、肺癌、胃癌、骨髓瘤和淋巴瘤患者风险更高。
  • 房颤与癌症共存提示预后较差,需加强综合管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer. METHODS: Using Dutch nationwide statistics, individuals with incident AF (n = 320 139) or cancer (n = 472 745) were identified during the period 2015-19. Dutch inhabitants without a history of AF (n = 320 135) or cancer (n = 472 741) were matched as control cohorts by demographic characteristics. Prevalence of cancer/AF at baseline, 1-year risk of cancer/AF diagnosis, and their time trends were determined. The association of cancer/AF diagnosis with all-cause mortality among those with AF/cancer was estimated by using time-dependent Cox regression. RESULTS: The rate of prevalence of cancer in the AF cohort was 12.6% (increasing from 11.9% to 13.2%) compared with 5.6% in the controls; 1-year cancer risk was 2.5% (stable over years) compared with 1.8% in the controls [adjusted hazard ratio (aHR) 1.52, 95% confidence interval (CI) 1.46-1.58], which was similar by cancer type. The rate of prevalence of AF in the cancer cohort was 7.5% (increasing from 6.9% to 8.2%) compared with 4.3% in the controls; 1-year AF risk was 2.8% (stable over years) compared with 1.2% in the controls (aHR 2.78, 95% CI 2.69-2.87), but cancers of the oesophagus, lung, stomach, myeloma, and lymphoma were associated with higher hazards of AF than other cancer types. Both cancer diagnosed after incident AF (aHR 7.77, 95% CI 7.45-8.11) and AF diagnosed after incident cancer (aHR 2.55, 95% CI 2.47-2.63) were associated with all-cause mortality, but the strength of the association varied by cancer type. CONCLUSIONS: Atrial fibrillation and cancer were associated bidirectionally and were increasingly coexisting, but AF risk varied by cancer type. Coexisting AF and cancer were negatively associated with survival.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chen Q, van Rein N, van der Hulle T, et al. Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study. Eur Heart J. 2024. PMID: 38619538. doi:10.1093/eurheartj/ehae222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。